Objective To observe the expression and clinical significance of kang ai 1 (Kai1) in the process from the progression from colorectal polyps to cancer, invasion and metastasis.Methods Immunohistochemistry was used to examine the expression of Kai1 in the colorectal tissues, colorectal adenoma tissues and colorectal carcinoma tissues.Real-time fluorescent quantitative polymerase chain reaction (FQ-PCR) was used to detect Kai1 mRNA expression.Results The expression of Kai1 protein was positive in 18 cases of colorectal carcinoma (45.00%), significantly lower than that in colorectal adenoma (91.25%) and colorectal tissues (100.00%), respectively, with significant differences among them (P=0.031).FQ-PCR showed that the expression of Kai1 mRNA in colorectal carcinoma, colorectal adenoma and normal colorectal mucosa was incresed by 2.038±0.933, 9.983±4.337 and 12.260±2.182 respectively (F=11.960, P=0.015).The expression of Kai1 protein and mRNA had a significant correlation with the lymph node metastasis of patients with colorectal carcinoma (P=0.011).ConclusionThe abnormal expression of Kai1 protein and mRNA is related with the carcinogenesis and the development of colorectal carcinoma.

Objective To investigate the effects of rosiglitazone,a ligand of peroxisome proliferators activated receptor gamma (PPAR-γ),on the expression of matrix metalloproteinase (MMP)-2 and MMP-9 in hepatic stellate cells (HSCs).Methods HSCs were cultured in medium containing different concentrations of rosiglitazone (5,10,15,20 μmol/L respectively),and harvested at 24 h.The expression of MMP-2 and MMP-9 was detected by using reverse transcription polymerase chain reaction.Results The MMP-2 expression in HSCs cultured with different concentrations of rosiglitazone (5,10,15,20 μmol/L)was 0.5708 ±0.0609,0.8900 ±0.0823,1.1348 ±0.1205 and 1.4490 ±0.0832 respectively,and it in control group was 0.3237 ± 0.0796.The MMP-9 expression in HSCs cultured with different concentrations of rosiglitazone (5,10,15,20 μmol/L) was 0.5487 ±0.0770,0.7554 ±0.0510,0.9497 ±0.0451 and 1.1088 ±0.0777 respectively,and it in control group was 0.3220 ±0.0592.Conclusion PPAR-γ ligand rosiglitazone may up-regulate the expression of MMP-2 and MMP-9 in HSCs dose-dependently to some extent.